AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · IEX Real-Time Price · USD
2.630
-0.300 (-10.24%)
Jul 26, 2024, 4:00 PM EDT - Market closed
AEON Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
102.89M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
111, Inc. | 2.05B |
Sensus Healthcare | 31.66M |
Aclaris Therapeutics | 31.12M |
Elutia | 28.99M |
Armata Pharmaceuticals | 4.70M |
Sagimet Biosciences | 2.00M |
VistaGen Therapeutics | 1.06M |
Cardiff Oncology | 610.00K |
AEON News
- 2 months ago - AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan - GlobeNewsWire
- 2 months ago - AEON Biopharma Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - AEON Biopharma Provides Update on Development Pipeline - GlobeNewsWire
- 3 months ago - AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine - GlobeNewsWire
- 4 months ago - CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants - GlobeNewsWire
- 4 months ago - AEON Biopharma Announces Redemption of Public Warrants - GlobeNewsWire
- 4 months ago - AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 4 months ago - AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine - GlobeNewsWire